@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix hgnc: . @prefix proteinModification: . @prefix psimod: . @prefix obo: . @prefix occursIn: . @prefix hasAnnotation: . @prefix species: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 occursIn: obo:CLO_0003684, species:9606; hasAnnotation: sub:_2; belv:variantOf hgnc:14063; a proteinModification:, psimod:01149 . sub:_2 dct:subject "TextLocation"; rdf:value "Results" . sub:assertion rdfs:label "p(HGNC:HDAC4,pmod(S,K,559))" . } sub:provenance { beldoc: dce:description "Approximately 2000 hand curated statements drawn from 57 PubMeds."; dce:rights "Copyright (c) 2011-2012, Selventa. All Rights Reserved."; dce:title "BEL Framework Small Corpus Document"; dct:license "Creative Commons Attribution-Non-Commercial-ShareAlike 3.0 Unported License"; pav:authoredBy sub:_4; pav:version "20131211" . sub:_3 prov:value """Thus Lys559, which lies within the N-terminal extension of class II HDACs, is required for sumoylation of HDAC4 in vitro and in vivo and is likely to be the predominant modification site for SUMO."""; prov:wasQuotedFrom pubmed:12032081 . sub:_4 rdfs:comment "support@belframework.org"; rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:12032081; prov:wasDerivedFrom beldoc:, sub:_3 . } sub:pubinfo { this: dct:created "2014-07-03T14:31:18.097+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }